Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
about
Genetics of psoriasis and pharmacogenetics of biological drugsAnti-TNF agents for paediatric psoriasisSystemic pharmacological treatments for chronic plaque psoriasisAnti-TNF agents for paediatric psoriasisEmerging therapies for the treatment of psoriasisThe origin and role of innate lymphoid cells in the lungNail Psoriasis: A Review of Treatment OptionsTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesThe Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTHTargeting Th17 Cells with Small Molecules and Small Interference RNAManaging Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewMaking the next steps in psoriatic arthritis management: current status and future directionsScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseReview: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyondNew era of biologic therapeutics in atopic dermatitisJakpot! New small molecules in autoimmune and inflammatory diseasesDiversity of IL-17-producing T lymphocytesCrystal structures of interleukin 17A and its complex with IL-17 receptor AManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisNew targets in psoriatic arthritisEffect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesImmune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic TargetsDevelopment of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to SkinTransient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cellsLinker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency.Weighing in on autoimmune disease: Big data tip the scale.Rationale and early clinical data on IL-17 blockade in psoriasis.Biologic agents in nail psoriasis: efficacy data and considerations.Anti-IL-17 phase II data for psoriasis: A review.First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisEfficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets.Counter-regulation of T cell effector function by differentially activated p38.Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapyRecent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.New insights of T cells in the pathogenesis of psoriasis
P2860
Q21284816-5047D551-16CD-4334-A051-DBC1D101575BQ24187673-26D5C786-828B-4F90-9429-0B2822257B52Q24188334-77ECF872-9B74-4A2D-8F35-2C4196ADC470Q24201907-E615C401-5155-4DA0-ADC4-43B4C8D00EE1Q24605738-0D7BD828-C56E-4125-9A92-5F3C71198BC4Q26740079-E6AAECC9-12D7-4653-8BE6-9134B43E7CBEQ26753038-33619E89-3C03-429D-963C-55BF79781A37Q26764867-6BE142A4-07A7-4862-A4F0-95686AA6601AQ26765844-50B242E2-5499-473A-AC3A-94A3793B4C39Q26770523-C00A87DA-442C-4B96-9AE0-3542A5EF7996Q26771785-4906EDC9-BBC8-48F1-B219-7590AC138A47Q26774874-504D4E29-6957-4498-B765-A659536521E8Q26783506-C812350C-D341-488A-91B0-0636A60F1C39Q26798209-024E1C53-1D30-42F2-B2C1-4B63D2E84831Q26800937-6DC9B1A0-4152-4D57-AFF6-7A950E2406FBQ26801173-03D21017-F649-4B0E-BB5E-0CC9F014EF27Q26991709-13C19D60-E822-43F0-BB1D-A772FEC5E90EQ27001941-D1DA7EB4-EAD8-428D-99B8-FB2F63596836Q27001957-32F98797-333A-4E0C-B728-45D4DE86D78FQ27010199-22F99A4C-6BC7-4D1C-98E4-77BE30C9ECA9Q27684681-D4CFCD9A-B7F4-435C-8177-7DB4ABE41818Q27693878-AF2D555E-57EE-4638-915A-AE65054D5A75Q28069592-334C498E-1BD2-4666-AE39-C4793A3AB782Q28076496-5B024A16-66AE-4619-8BFF-16E6E651913AQ28079713-F4D03B72-8640-4252-B7A4-EA88CFFE5867Q28550171-74E2E826-4479-4A61-879F-0208E0DFBBAAQ28829881-2606BC0C-4C68-45F3-958A-E97264B51EC6Q30009438-55B6178B-9A0D-4BD2-8175-AC9A50D995A9Q30587275-3971262D-61C6-4C22-AEEB-81B39E75D4D4Q30658185-235B6299-0869-4AFA-B938-FC73730B6092Q30683539-80326355-EF74-4C41-80D9-FAC65BC003A5Q30760301-D3060D5F-91FE-4EC6-A5A8-6E1C31C1ADFBQ33593625-A3771EA0-0782-412C-8B40-B944A73E8FE6Q33626095-A2A90883-B55B-40F6-A98F-763236AFD36FQ33642954-CE45A6ED-647E-4B6E-B10C-677C90AEA29DQ33702970-127BB5B7-C6F4-43DA-8610-2BE1F0A51D54Q33785074-7CEB60A2-3D2D-40F5-9DCA-694654A4F124Q33872389-5D4E85A5-4725-4A0C-8F71-EE9FC5D1739EQ33969217-2D0D9B3E-1060-49AD-98C3-80CB0A945355Q34043846-4DDDD8E4-4048-4947-A108-A75BE7F824DD
P2860
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
description
article
@en
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2012
@uk
name
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
@en
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
@nl
type
label
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
@en
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
@nl
prefLabel
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
@en
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
@nl
P2093
P356
P1476
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
@en
P2093
Craig Leonardi
Daniel Braun
Emily Edson-Heredia
Gregory Cameron
Robert Matheson
Subhashis Banerjee
P304
P356
10.1056/NEJMOA1109997
P407
P577
2012-03-01T00:00:00Z